Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Gains from Investment Securities: 2021-2025

Historic Gains from Investment Securities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $17.1 million.

  • ARS Pharmaceuticals' Gains from Investment Securities rose 12.70% to $17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 12.70%. This contributed to the annual value of $15.2 million for FY2024, which is 31.91% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Gains from Investment Securities stood at $17.1 million, which was up 5,602.20% from $300,000 recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Gains from Investment Securities high stood at $17.1 million for Q3 2025, and its period low was -$1,000 during Q1 2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $6.2 million (2023), whereas its average is $7.9 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 1,558,541.90% in 2023, then slumped by 90.97% in 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $100,000 in 2021, then rose by 8.90% to $7.0 million in 2022, then tumbled by 68.69% to $600,000 in 2023, then spiked by 1,433.33% to $9.2 million in 2024, then increased by 12.70% to $17.1 million in 2025.
  • Its Gains from Investment Securities was $17.1 million in Q3 2025, compared to $300,000 in Q2 2025 and $1.3 million in Q1 2025.